



Ref: STEX/Clarification/NSE/2024-25

Date: 15.03.2025

National Stock Exchange of India Ltd
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex, Bandra (E)
Mumbai – 400 051

NSE Code: SHIVALIK

Sub: Submission of clarification on Quick Results for the quarter ended on December 31, 2024

Dear Sir,

This has reference to the email received from your good office on March 05, 2025 with following observations:

- 1. Financial results submitted is not as per format prescribed under Schedule III of the Companies Act, 2013.
Profit and EPS incorrect in Consolidated XBRL**
- 2. Machine Readable Form / Legible copy of Financial Results not submitted.**

Reply: Inadvertently filled incorrect XBRL results, revised XBRL Consolidated Results for the quarter ended 31.12.2024 is hereby attached also find attached legible copy of financial results.

Kindly take the same on your records and oblige.

Thanking You

Yours truly,
For Shivalik Rasayan Limited

Parul Choudhary
Company Secretary & Compliance Officer
ACS: 34854

Ref: STEX/OUTCOME/2024-25

Date: 11.02.2025

BSE Limited

Department of Corporate Services-Listing
PJ Towers, Dalal Street
Mumbai- 400001

National Stock Exchange of India Limited

Exchange Plaza, Bandra Kurla Complex
Bandra (E) Mumbai- 400051

Scrip Code: 539148

Symbol: SHIVALIK

Sub. : Outcome of Board Meeting

Dear Sir,

We wish to inform you that the Board of Directors of the Company at its meeting held today approved the Un-Audited Financial Results (Standalone and Consolidated) of the Company for the quarter & nine months ended on December 31, 2024.

Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose the following:

- Statement showing the Un-Audited Financial Results (Standalone & Consolidated) of the Company for the quarter & nine months ended on December 31, 2024 as **Annexure-A** and
- Unaudited Segment-wise Revenue, Results, Assets and Liabilities of the Company, both Standalone and Consolidated, for the quarter & nine months ended on December 31, 2024; as **Annexure-B** and
- Limited Review Report from Rahul Chaudhary & Associates, Chartered Accountant on the Un- Audited Financial Results (Standalone & Consolidated) as **Annexure-C**

The meeting of the Board of Directors commenced 4.00 p.m. and concluded at 5.20 p.m.

The Un-Audited Financial Results (Standalone & Consolidated) of the Company for the quarter & nine months ended on December 31, 2024, as approved by the Board, will also be available on the Company's website www.shivalikrasayan.com.

This is for your information and records.

Thanking You.

Yours faithfully,

For Shivalik Rasayan Limited

Parul Choudhary

Company Secretary & Compliance Officer

ACS: 34854



Shivalik Rasayan Ltd.

Regd. Office: Village Kolhupani, P.O. Chandanwari, Dehradun- 248007

CIN : L24237UR1979PLC005041


E-mail : cs@shivalikrasayan.com, www.shivalikrasayan.com

Un-audited Standalone and Consolidated Financial Results for the Quarter ended 31st Dec' 2024

All Figures in Rs. Lacs Excepts Earning Per Shares

PART I		Standalone						Consolidated					
		Three month period ended			Nine Months		Year Ended	Three month period ended			Nine Months		Year Ended
		31-12-2024	30-09-2024	31-12-2023	31-12-2024	31-12-2023	31.03.2024	31-12-2024	30-09-2024	31-12-2023	31-12-2024	31-12-2023	31.03.2024
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Income from operations												
	(a) Net Sales/Income from operations	4,016.39	3,769.93	2,373.18	10,944.43	6,976.09	9,367.63	8,530.61	8,244.27	7,023.40	24,237.85	20,174.76	27,298.25
	(b) Other Income	146.34	6.47	67.11	158.00	72.56	165.15	160.41	35.43	150.16	259.66	248.51	397.72
	Total Revenue	4,162.73	3,776.40	2,440.29	11,102.43	7,048.65	9,532.78	8,691.02	8,279.70	7,173.56	24,497.51	20,423.27	27,695.97
2	Expenses												
	a) Cost of Material Consumed	2,572.91	2,340.05	1,007.06	6,534.56	3,458.51	5,137.90	5,425.15	5,234.49	3,916.81	14,447.81	11,745.98	15,607.70
	b) Purchase of Stock-in-Trade	-	-	-	-	-	-	-	-	-	-	-	-
	c) Changes in inventory of Finished Goods and Work in Progress	(530.68)	(448.10)	131.58	(858.73)	(59.71)	(413.23)	(1,150.85)	(898.44)	(279.91)	(1,686.63)	(1,447.03)	(1,623.26)
	d) Employees Benefits Expenses	591.00	634.27	467.57	1,671.43	1,234.14	1,675.26	1,391.50	1,397.70	1,268.71	4,018.90	3,401.51	4,681.84
	e) Finance Cost	149.57	140.90	93.41	411.82	250.57	322.93	225.52	245.00	158.07	662.44	501.60	762.65
	f) Depreciation and Amortisation Expenses	262.56	204.96	120.53	640.00	394.58	528.39	483.53	465.69	301.02	1,298.73	926.46	1,237.71
	g) Other expenses	723.04	599.29	369.94	1,699.18	1,003.08	1,273.92	1,534.15	1,334.59	1,231.44	4,013.12	3,485.27	4,714.16
	Total Expenses	3,768.40	3,471.37	2,190.09	10,098.26	6,281.17	8,525.17	7,909.00	7,779.03	6,596.14	22,754.37	18,613.79	25,380.80
3	Profit/(Loss) before Exceptional Items & Tax (1-2)	394.33	305.03	250.20	1,004.17	767.48	1,007.61	782.02	500.67	577.42	1,743.14	1,809.48	2,315.17
4	Exceptional Items (Commercial Tax Expenses Related to Earlier Year)	-	-	-	-	-	-	-	-	-	-	-	-
5	Profit/(Loss) before Extra Ordinary Items & Tax (3-4)	394.33	305.03	250.20	1,004.17	767.48	1,007.61	782.02	500.67	577.42	1,743.14	1,809.48	2,315.17
6	Tax Expenses												
	Current Year	68.90	53.29	61.23	175.45	197.49	182.84	171.47	158.54	159.84	466.83	540.06	604.53
	MAT Credit Entitlement	(63.90)	(53.29)	(17.51)	(170.45)	(63.39)	-	(63.90)	(53.29)	(17.51)	(170.45)	(63.39)	-
	Deferred Tax Liability	(12.26)	(40.46)	(24.83)	(54.83)	31.76	(32.93)	(19.34)	(47.20)	0.79	(76.44)	(14.17)	(96.46)
	Total Tax Expenses	(7.26)	(40.46)	18.89	(49.83)	165.86	149.92	88.23	58.05	143.12	219.94	462.50	508.08
7	Net Profit/Loss for the period (5-6)	401.59	345.49	231.31	1,054.00	601.62	857.69	693.79	442.62	434.30	1,523.20	1,346.98	1,807.09
8	Other Comprehensive Income												
	Item that will not be reclassified to Profit & Loss	-	-	-	-	-	-	-	-	-	-	-	-
	Total Comprehensive income Net of Tax	401.59	345.49	231.31	1,054.00	601.62	857.69	693.79	442.62	434.30	1,523.20	1,346.98	1,807.09
9	Total Comprehensive income for the Period (7+8)	401.59	345.49	231.31	1,054.00	601.62	857.69	693.79	442.62	434.30	1,523.20	1,346.98	1,807.09

R. B. Sharma



Particulars	Standalone						Consolidated					
	Three month period ended			Nine Months		Year Ended	Three month period ended			Nine Months		Year Ended
	31-12-2024	30-09-2024	31-12-2023	31-12-2024	31-12-2023	31.03.2024	31-12-2024	30-09-2024	31-12-2023	31-12-2024	31-12-2023	31.03.2024
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	Unaudited	Unaudited	Audited	Unaudited	Unaudited	Audited
10 Net Profit/ (loss) attributable to												
a) Controlling Interest	401.59	345.49	231.31	1,054.00	601.62	857.69	527.21	400.88	306.23	1,255.70	911.91	1,636.01
b) Non Controlling Interest	-	-	-	-	-	-	166.58	41.75	128.07	267.50	435.07	171.08
11 Paid-up equity share capital (Rs.5/- per share)	778.01	778.01	778.01	778.01	778.01	778.01	778.01	778.01	778.01	778.01	778.01	778.01
12 Earning Per Share (Rs.)												
(a) Basic	2.58	2.22	1.55	6.77	4.04	5.63	3.39	2.58	2.03	8.07	6.13	10.75
(b) Diluted	2.58	2.22	1.55	6.77	4.04	5.63	3.39	2.58	2.03	8.07	6.13	10.75

NOTES :

- 1 The Un-audited financial results for the quarter ended 31.12.2024 have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 11.02.2025.
- 2 The figures are regrouped in previous year also, wherever considered necessary.
- 3 The company operates in business segment viz Agro Chemical, Pharma API & Pharma Formulations.
- 4 The Green Field Plant to manufacture agro chemical has now been commissioned and the trials are underway.
- 5 The other expenses includes Salary of R&D team and plant operating expenses of API facility, Dahej, Gujarat
- 6 The Earning Per Share has been calculated as per Ind AS-33.
- 7 Consolidated results of the company includes the results of its Associate i.e., Medicamen Biotech Limited.
- 8 Limited Review Report has been carried out by the Statutory Auditors for the above period.

For & on behalf of Board of Directors
Shivalik Rasayan Limited



R. Bishnoi
(Rahul Bishnoi)
Chairman

Place : New Delhi

Dated : 11.02.2025



Shivalik Rasayan Ltd.

Regd. Office: Village Kolhupani, P.O. Chandanwari, Dehradun- 248007

CIN : L24237UR1979PLC005041

E-mail : cs@shivalikrasayan.com, www.shivalikrasayan.com

Unaudited Standalone & Consolidated segment wise revenue, results, assets and liabilities for the Quarter Ended 31st Dec' 2024

All Figures in Lacs

Sl. No.	Particulars	Standalone						Consolidated					
		Three months period ended			Nine Months		Year Ended	Three month period ended			Nine Months		Year Ended
		31-12-2024	30-09-2024	31-12-2023	31-12-2024	31-12-2023	31-03-2024	31-12-2024	30-09-2024	31-12-2023	31-12-2024	31-12-2023	31-03-2024
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Segment revenue												
	A. Agrochemicals	3,785.51	3,601.98	2,305.06	10,363.72	6,587.91	8,845.38	3,785.51	3,601.98	2,305.06	10,363.72	6,587.91	8,845.38
	B. Active Pharma Ingredient (API)	230.88	167.95	68.12	580.71	388.18	522.25	230.88	167.95	68.12	580.71	388.18	522.25
	C. Pharma Formulation	-	-	-	-	-	-	4,514.22	4,474.34	4,650.22	13,293.42	13,198.67	17,930.62
	D. Unallocated other operating revenue	-	-	-	-	-	-	-	-	-	-	-	-
	Total Revenue	4,016.39	3,769.93	2,373.18	10,944.43	6,976.09	9,367.63	8,530.61	8,244.27	7,023.40	24,237.85	20,174.76	27,298.25
2	Segment results												
	A. Agrochemicals	718.61	720.30	67.21	2,097.27	933.60	1,332.54	718.61	720.30	67.21	2,097.27	933.60	1,332.54
	B. Active Pharma Ingredient (API)	(174.71)	(274.38)	276.39	(681.29)	84.45	(2.01)	(174.71)	(274.38)	276.39	(681.29)	84.45	(2.01)
	C. Pharma Formulation	-	-	-	-	-	-	463.65	299.73	391.88	989.59	1,293.03	1,747.28
	Sub Total	543.90	445.92	343.60	1,415.98	1,018.05	1,330.53	1,007.55	745.65	735.48	2,405.57	2,311.08	3,077.81
	Less: Finance costs	149.57	140.90	93.41	411.82	250.57	322.92	225.52	244.98	158.07	662.44	501.60	762.64
	Less: Unallocable expenditure net of unallocable income	-	-	-	-	-	-	-	-	-	-	-	-
	Profit before exceptional items and tax	394.33	305.03	250.20	1,004.17	767.48	1,007.61	782.02	500.67	577.42	1,743.14	1,809.48	2,315.17
	Exceptional Items	-	-	-	-	-	-	-	-	-	-	-	-
	Profit/(Loss) before tax	394.33	305.03	250.20	1,004.17	767.48	1,007.61	782.02	500.67	577.42	1,743.14	1,809.48	2,315.17
	Less: Tax Expenses	(7.26)	(40.46)	18.88	(49.83)	165.85	149.92	88.23	58.05	143.11	219.94	462.49	508.08
	Net Profit/(Loss) for the period/year	401.59	345.49	231.31	1,054.00	601.62	857.69	693.78	442.62	434.30	1,523.20	1,346.98	1,807.09
3	Segment assets												
	A. Agrochemicals	30,671.16	30,843.31	26,740.08	30,671.16	26,740.08	35,844.56	30,671.16	30,843.31	26,740.08	30,671.16	26,740.08	35,844.56
	B. Active Pharma Ingredient (API)	11,224.59	11,078.07	11,749.96	11,224.59	11,749.96	11,259.83	11,224.59	11,078.07	11,749.96	11,224.59	11,749.96	11,259.83
	C. Pharma Formulation	-	-	-	-	-	-	29,217.50	29,452.24	28,993.77	29,217.50	28,993.77	29,452.24
	D. Unallocated	-	-	-	-	-	-	-	-	-	-	-	-
4	Total	41,895.76	41,921.39	38,490.04	41,895.76	38,490.04	47,104.39	71,113.26	71,373.62	67,483.81	71,113.26	67,483.81	76,556.63
	Segment liabilities												
	A. Agrochemicals	10,644.76	11,043.55	7,391.55	10,644.76	7,391.55	6,814.88	10,644.76	11,043.55	7,391.55	10,644.76	7,391.55	6,814.88
	B. Active Pharma Ingredient (API)	409.63	323.52	226.37	409.63	226.37	407.85	409.63	323.52	226.37	409.63	226.37	407.85
	C. Pharma Formulation	-	-	-	-	-	-	6,210.07	8,905.11	8,839.86	6,210.07	8,839.86	5,800.50
	D. Unallocated	-	-	-	-	-	-	-	-	-	-	-	-
	Total	11,054.39	11,367.07	7,617.92	11,054.39	7,617.92	7,222.73	17,264.47	20,272.18	16,457.78	17,264.47	16,457.78	13,023.23

For & on behalf of Board of Directors
Shivalik Rasayan Limited



R. Bishnoi
(Rahul Bishnoi)
Chairman

Place : New Delhi
Dated : 11.02.2025



RAHUL CHAUDHARY & ASSOCIATES

Chartered Accountants

LIMITED REVIEW REPORT ON UNAUDITED QUARTERLY AND YEAR-TO-DATE STANDALONE FINANCIAL RESULTS OF SHIVALIK RASAYAN LIMITED UNDER REGULATION 33 OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015

To

The Board of Directors,
Shivalik Rasayan Ltd.
Village Kolhupani, P.O.
Chandanwari, Dehradun-248007

We have reviewed the accompanying statement of unaudited financial results of M/s Shivalik Rasayan Limited having its corporate office situated at 1506, Chiranjiv Tower, 43, Nehru Place, New Delhi-110019 for the quarter and nine months ended December 31, 2024 ("the statement") being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS - 34"), prescribed under Section 133 of the Companies Act, 2013 ("the Act"), and other accounting principles generally accepted in India and in compliance with Regulation 33 and Regulation 52 read with Regulation 63(2) of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 and Regulation 52 read with Regulation 63(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For M/s Rahul Chaudhary & Associates

Rahul Chaudhary
M. No. 542837
Firm Reg. No. 033971N



Place: Faridabad
Date: 11.02.2025
UDIN:- 25542837BMOQWK5501



RAHUL CHAUDHARY & ASSOCIATES

Chartered Accountants

LIMITED REVIEW REPORT ON UNAUDITED QUARTERLY AND YEAR-TO-DATE CONSOLIDATED FINANCIAL RESULTS OF SHIVALIK RASAYAN LIMITED UNDER REGULATION 33 OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015

To

The Board of Directors,
Shivalik Rasayan Ltd.
Village Kolhupani, P.O.
Chandanwari, Dehradun-248007

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of SHIVALIK RASAYAN LIMITED ("the Parent") and its associate (the Parent and its associate together referred to as "the Group"), and its share of the net profit after tax and total comprehensive income of its associate for the quarter and nine months ended December 31, 2024 ("the Statement") being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

5. The Statement includes the results of the Medicamen Biotech Limited (the "Associate" Company)
6. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6 and 7(ii) below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended including the manner in which it is to be disclosed, or that it contains any material misstatement.





RAHUL CHAUDHARY & ASSOCIATES

Chartered Accountants

7. The Statements includes the Group's share of net profit after tax of Rs. 292.20/- Lakhs for the quarter and Rs.469.19/- Lakhs for the nine months ended on December 31, 2024 respectively, as considered in the consolidated unaudited financial results, in respect of an associate, based on their interim financial information which has not been reviewed by their auditors. According to the information and explanations given to us by the Management, these interim financial informations are not material to the Group. Our conclusion on the Statement is not modified in respect of the above matter.

Our conclusion on the Statement is not modified in respect of the above matter.

For M/s Rahul Chaudhary & Associates

Rahul Chaudhary
M. No. 542837
Firm Reg. No. 033971N



Place: Faridabad
Date: 11.02.2025
UDIN: 25542837BMOQWL4592

General information about company	
Scrip code	539148
NSE Symbol	SHIVALIK
MSEI Symbol	NA
ISIN*	INE788J01021
Name of company	Shivalik Rasayan Limited
Type of company	
Class of security	Equity
Date of start of financial year	01-04-2024
Date of end of financial year	31-03-2025
Date of board meeting when results were approved	11-02-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange	04-02-2025
Description of presentation currency	INR
Level of rounding used in financial results	Lakhs
Reporting Quarter	Third quarter
Nature of report standalone or consolidated	Consolidated
Whether results are audited or unaudited	Unaudited
Segment Reporting	Multi segment
Description of single segment	
Start date and time of board meeting	11-02-2025 16:00
End date and time of board meeting	11-02-2025 17:20
Whether cash flow statement is applicable on company	
Type of cash flow statement	
Declaration of unmodified opinion or statement on impact of audit qualification	Not applicable

Financial Results – Ind-AS			
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-10-2024	01-04-2024
B	Date of end of reporting period	31-12-2024	31-12-2024
C	Whether results are audited or unaudited	Unaudited	Unaudited
D	Nature of report standalone or consolidated	Consolidated	Consolidated
Part I	Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.		
1	Income		
	Revenue from operations	8530.61	24237.85
	Other income	160.41	259.66
	Total income	8691.02	24497.51
2	Expenses		
(a)	Cost of materials consumed	5425.15	14447.81
(b)	Purchases of stock-in-trade	0	0
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	-1150.85	-1686.63
(d)	Employee benefit expense	1391.5	4018.9
(e)	Finance costs	225.52	662.44
(f)	Depreciation, depletion and amortisation expense	483.53	1298.73
(f)	Other Expenses		
1	Other Expenses	1534.15	4013.12
10			
	Total other expenses	1534.15	4013.12
	Total expenses	7909	22754.37

Financial Results – Ind-AS			
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-10-2024	01-04-2024
B	Date of end of reporting period	31-12-2024	31-12-2024
C	Whether results are audited or unaudited	Unaudited	Unaudited
D	Nature of report standalone or consolidated	Consolidated	Consolidated
Part I	Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.		
3	Total profit before exceptional items and tax	782.02	1743.14
4	Exceptional items	0	0
5	Total profit before tax	782.02	1743.14
7	Tax expense		
8	Current tax	107.57	296.38
9	Deferred tax	-19.34	-76.44
10	Total tax expenses	88.23	219.94
11	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0	0
14	Net Profit Loss for the period from continuing operations	693.79	1523.2
15	Profit (loss) from discontinued operations before tax	0	0
16	Tax expense of discontinued operations	0	0
17	Net profit (loss) from discontinued operation after tax	0	0
19	Share of profit (loss) of associates and joint ventures accounted for using equity method	0	0
21	Total profit (loss) for period	693.79	1523.2
22	Other comprehensive income net of taxes	0	0

Financial Results – Ind-AS			
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-10-2024	01-04-2024
B	Date of end of reporting period	31-12-2024	31-12-2024
C	Whether results are audited or unaudited	Unaudited	Unaudited
D	Nature of report standalone or consolidated	Consolidated	Consolidated
Part I	Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.		
23	Total Comprehensive Income for the period	693.79	1523.2
24	Total profit or loss, attributable to		
	Profit or loss, attributable to owners of parent		
	Total profit or loss, attributable to non-controlling interests		
25	Total Comprehensive income for the period attributable to		
	Comprehensive income for the period attributable to owners of parent	0	0
	Total comprehensive income for the period attributable to owners of parent non-controlling interests	0	0
26	Details of equity share capital		
	Paid-up equity share capital	778.01	778.01
	Face value of equity share capital	5	5
27	Details of debt securities		
28	Reserves excluding revaluation reserve		
29	Earnings per share		
i	Earnings per equity share for continuing operations		
	Basic earnings (loss) per share from continuing operations	3.39	8.07
	Diluted earnings (loss) per share from continuing operations	3.39	8.07
ii	Earnings per equity share for discontinued operations		
	Basic earnings (loss) per share from discontinued operations	0	0
	Diluted earnings (loss) per share from discontinued operations	0	0
ii	Earnings per equity share		
	Basic earnings (loss) per share from continuing and discontinued operations	3.39	8.07
	Diluted earnings (loss) per share from continuing and discontinued operations	3.39	8.07
30	Debt equity ratio		
31	Debt service coverage ratio		
32	Interest service coverage ratio		
33	Disclosure of notes on financial results		

Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results			
Particulars		3 months/ 6 month ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period		01-10-2024	01-04-2024
Date of end of reporting period		31-12-2024	31-12-2024
Whether accounts are audited or unaudited		Unaudited	Unaudited
Nature of report standalone or consolidated		Consolidated	Consolidated
1 Segment Revenue (Income)			
(net sale/income from each segment should be disclosed)			
1	Agrochemicals	3785.51	10363.72
2	Active Pharma Ingredients (API)	230.88	580.71
3	Pharma Formulation	4514.22	13293.42
	Total Segment Revenue	8530.61	24237.85
	Less: Inter segment revenue	0	0
	Revenue from operations	8530.61	24237.85
2 Segment Result			
Profit (+) / Loss (-) before tax and interest from each segment			
1	Agrochemicals	718.61	2097.27
2	Active Pharma Ingredients (API)	-174.71	-681.29
3	Pharma Formulation	463.65	989.59
	Total Profit before tax	1007.55	2405.57
	i. Finance cost	225.53	662.43
	ii. Other Unallocable Expenditure net off Unallocable income	0	0
	Profit before tax	782.02	1743.14
3 (Segment Asset - Segment Liabilities)			
Segment Asset			
1	Agrochemicals	30671.17	30671.17
2	Active Pharma Ingredients (API)	11224.59	11224.59
3	Pharma Formulation	29217.5	29217.5
	Total Segment Asset	71113.26	71113.26
	Un-allocable Assets	0	0
	Net Segment Asset	71113.26	71113.26
4 Segment Liabilities			
Segment Liabilities			
1	Agrochemicals	10644.76	10644.76
2	Active Pharma Ingredients (API)	409.63	409.63
3	Pharma Formulation	6210.08	6210.08
	Total Segment Liabilities	17264.47	17264.47
	Un-allocable Liabilities	0	0
	Net Segment Liabilities	17264.47	17264.47
Disclosure of notes on segments			

